BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23572558)

  • 1. Constitutively active ALK2 receptor mutants require type II receptor cooperation.
    Bagarova J; Vonner AJ; Armstrong KA; Börgermann J; Lai CS; Deng DY; Beppu H; Alfano I; Filippakopoulos P; Morrell NW; Bullock AN; Knaus P; Mishina Y; Yu PB
    Mol Cell Biol; 2013 Jun; 33(12):2413-24. PubMed ID: 23572558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
    Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
    Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
    Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.
    Le VQ; Wharton KA
    Dev Dyn; 2012 Jan; 241(1):200-14. PubMed ID: 22174087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.
    Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC
    J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
    Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
    Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BMP type I receptor inhibition reduces heterotopic [corrected] ossification.
    Yu PB; Deng DY; Lai CS; Hong CC; Cuny GD; Bouxsein ML; Hong DW; McManus PM; Katagiri T; Sachidanandan C; Kamiya N; Fukuda T; Mishina Y; Peterson RT; Bloch KD
    Nat Med; 2008 Dec; 14(12):1363-9. PubMed ID: 19029982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
    Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
    J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
    Luo Y; Alsamarah A; Zhang K; Hao J
    Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
    Davis AJ; Brooijmans N; Brubaker JD; Stevison F; LaBranche TP; Albayya F; Fleming P; Hodous BL; Kim JL; Kim S; Lobbardi R; Palmer M; Sheets MP; Vassiliadis J; Wang R; Williams BD; Wilson D; Xu L; Zhu XJ; Bouchard K; Hunter JW; Graul C; Greenblatt E; Hussein A; Lyon M; Russo J; Stewart R; Dorsch M; Guzi TJ; Kadambi V; Lengauer C; Garner AP
    Sci Transl Med; 2024 May; 16(749):eabp8334. PubMed ID: 38809966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMPR2 inhibits activin and BMP signaling via wild-type ALK2.
    Olsen OE; Sankar M; Elsaadi S; Hella H; Buene G; Darvekar SR; Misund K; Katagiri T; Knaus P; Holien T
    J Cell Sci; 2018 Jun; 131(11):. PubMed ID: 29739878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
    Katagiri T; Tsukamoto S; Kuratani M
    Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drosophila models of FOP provide mechanistic insight.
    Le V; Anderson E; Akiyama T; Wharton KA
    Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
    Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC
    Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.